Discontinue Sliding Scale and Start Basal Insulin Immediately
This patient with A1C 10% and fasting glucose 180 mg/dL requires immediate transition from sliding‑scale insulin to a structured basal insulin regimen, because sliding‑scale monotherapy is ineffective for outpatient diabetes management and the severe hyperglycemia (A1C >10%) mandates prompt basal insulin initiation. 1, 2
Why Sliding Scale Must Be Stopped
- Sliding‑scale insulin has no proven benefit for glycemic control and increases the risk of hypoglycemia and wide glucose fluctuations; guidelines have advised against it for nearly 20 years. 3, 4
- Sliding scale is reactive rather than proactive—it treats hyperglycemia after it occurs instead of preventing it, making it unsuitable for outpatient management of type 2 diabetes. 3, 5
- The only context where sliding scale may be acceptable is hospitalized patients with admission glucose <180 mg/dL, but even then basal‑bolus regimens are preferred. 6, 7
Immediate Basal Insulin Initiation
Start long‑acting basal insulin (glargine, degludec, or NPH) at 10 units per day OR 0.1–0.2 units/kg/day. 1, 2
- The American Diabetes Association (2025) explicitly recommends insulin as first‑line injectable therapy when A1C >10% because this degree of hyperglycemia reflects severe glucose toxicity that impairs pancreatic β‑cell function. 1, 2
- A fasting glucose of 180 mg/dL combined with A1C 10% confirms inadequate basal insulin coverage, making basal insulin the cornerstone of therapy. 2
Titration Protocol
Set a fasting plasma glucose target of 80–130 mg/dL and increase the basal dose by 2 units every 3 days until this target is reached without hypoglycemia. 1, 2
- This rapid titration schedule avoids prolonged uncontrolled hyperglycemia and is both safe and effective. 2
- If hypoglycemia occurs without an obvious cause (missed meal, increased activity), reduce the basal dose by 10–20%. 1, 2
Continue or Add Oral Agents
Continue metformin (if not contraindicated) when starting basal insulin; the combination reduces insulin requirements, limits weight gain, and lowers hypoglycemia risk compared to insulin alone. 2
Add a GLP‑1 receptor agonist (liraglutide, semaglutide, dulaglutide, or tirzepatide) either at insulin initiation or after basal optimization to achieve superior A1C reduction with weight loss rather than weight gain and less hypoglycemia. 1, 2
- Fixed‑ratio combinations (insulin degludec/liraglutide or insulin glargine/lixisenatide) are convenient options if both agents are needed. 1, 2
Monitoring and Intensification
Reassess every 3–6 months to avoid therapeutic inertia. 1, 2
Watch for over‑basalization: if the basal dose exceeds 0.5 units/kg/day (roughly 40–50 units/day) and A1C remains elevated, do not continue escalating basal insulin. 2
- Clinical clues include a large bedtime‑to‑morning glucose differential, high postprandial‑to‑preprandial differentials, frequent hypoglycemia, or marked glucose variability. 1, 2
- At this point, add prandial (rapid‑acting) insulin starting with 4 units or 10% of the basal dose before the largest meal, then titrate by 1–2 units every 3 days based on postprandial readings. 1, 2
Safety Measures
Prescribe glucagon for emergency treatment of severe hypoglycemia at the time insulin is started. 1, 2
Exclude type 1 diabetes before attributing the hyperglycemia solely to type 2 diabetes—look for rapid weight loss, ketosis, or autoantibodies, especially if the patient is lean or younger. 2
Common Pitfalls to Avoid
- Do not delay insulin initiation in a patient with A1C 10%; prompt treatment is essential to reverse glucose toxicity. 2
- Do not use overly conservative starting doses; 10 units or 0.1–0.2 units/kg/day is appropriate and safe. 1, 2
- Do not titrate too slowly; increase by 2 units every 3 days rather than waiting weeks between adjustments. 1, 2
- Do not continue sliding scale as the primary regimen for outpatient diabetes—it is ineffective and increases glucose variability. 3, 4